Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA5 | P08648 | 1/20 | 0.46 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.46 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20792633 | 0.93 | ITGA5 (0.42) | ITGA5ITGB6ITGB8MTORKCNH2 | |
| SCHEMBL30410775 | 0.91 | ITGA5 (0.46) | ITGA5ITGB6ITGB8MTORNTRK1 | |
| SCHEMBL20764688 | 0.91 | ITGA5 (0.46) | ITGA5ITGB6ITGB8MTORNTRK1 | |
| SCHEMBL23679179 | 0.85 | SLC6A2 (0.47) | ITGA5ITGB6ITGB8MTORNTRK1 | |
| SCHEMBL20792438 | 0.85 | ITGA5 (0.47) | ITGA5ITGB6ITGB8MTORNTRK1 | |
| SCHEMBL30412293 | 0.85 | ITGA5 (0.47) | ITGA5ITGB6ITGB8MTORNTRK1 | |
| SCHEMBL19283611 | 0.84 | ITGA5 (0.46) | ITGA5ITGB6ITGB8MTORNTRK1 | |
| SCHEMBL20743289 | 0.84 | ITGA5 (0.45) | ITGA5ITGB6ITGB8MTORNTRK1 | |
| SCHEMBL20743024 | 0.84 | ITGA5 (0.45) | ITGA5ITGB6ITGB8MTORNTRK1 | |
| SCHEMBL19283613 | 0.83 | ITGB6 (0.55) | ITGA5ITGB6ITGB8MTORNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111372928-B | Benzimidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2023-05-16 | — | — | CN | claimed |
| US-11168074-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2021-11-09 | — | — | US | claimed |
| EP-3672953-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-07-28 | — | — | EP | claimed |
| US-20200255409-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-08-13 | — | — | US | claimed |
| EP-3672953-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-07-01 | — | — | EP | claimed |
| WO-2019038315-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-28 | — | — | WO | claimed |
| CN-111372928-B | Benzimidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2023-05-16 | — | — | CN | disclosed |
| US-11168074-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2021-11-09 | — | — | US | disclosed |
| US-11168074-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2021-11-09 | — | — | US | disclosed |
| EP-3672953-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-07-28 | — | — | EP | disclosed |
| US-20200255409-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-08-13 | — | — | US | disclosed |
| US-20200255409-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-08-13 | — | — | US | disclosed |
| CN-111372928-A | Benzimidazole derivatives as potassium channel inhibitors | 阿塞西翁制药公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3672953-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019038315-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255409-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN1, KCNN2, KCNJ2 | ITGA5 3438/4885ITGB6 3377/4885ITGB8 3800/4885 |
| US-11168074-B2 | Potassium channel inhibitors | KCNN2, KCNJ2, KCNN1 | ITGA5 2901/4885ITGB6 2859/4885ITGB8 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.